Used primarily in pharmaceutical research as a key intermediate in the synthesis of immunomodulatory agents and targeted protein degraders such as PROTACs, particularly those involving BTK (Bruton's tyrosine kinase) for the treatment of autoimmune diseases, certain cancers including multiple myeloma, and inflammatory conditions. Its structure enables selective modulation of signaling pathways involved in cell proliferation, immune response, and inflammation. Due to its functional groups, particularly the glutarimide and piperazine moieties, it is employed in the development of PROTACs (proteolysis-targeting chimeras), where it serves as a cereblon E3 ligase ligand to facilitate targeted protein degradation. It also supports inhibition of cytokine production and immune modulation in medicinal chemistry applications. Commonly utilized for lead optimization due to its favorable solubility and binding properties.